European trials exploring afamelanotide for vitiligo and polymorphous light eruption exist but use the implant formulation, not injectable peptide
The LEADER trial (liraglutide) reported pancreatitis in 0.3% of liraglutide patients versus 0.1% of placebo patients over a median 3.8 years
Many patients who see weight loss by week 4 also made concurrent dietary changesthis synergy between pharmacological and behavioral interventions is where most dramatic, sustainable results emerge
Oral suspensions or sublingual drops for flexible dosing and ease of use
We have been prescribing many long-term drugs for hypertension, heart disease, high cholesterol, diabetes, arthritis, reflux, and many other diseases without hesitation
Drawing from representative and recent evidence, this review summarizes the role of inflammation in the pathogenesis and progression of EDC